Patents by Inventor Miles Carroll
Miles Carroll has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220275346Abstract: The present invention provides a viral vector or bacterial vector, said vector comprising a nucleic acid sequence encoding a Hantavirus nucleoprotein or antigenic fragment thereof; wherein said vector is capable of inducing a protective immune response in a subject. The present invention also provides compositions and uses of the vector in methods of medical treatment.Type: ApplicationFiled: July 29, 2020Publication date: September 1, 2022Applicant: SECRETARY OF STATE FOR HEALTH AND SOCIAL CAREInventors: Roger Hewson, Stuart Dowall, Emma Kennedy, Miles Carroll
-
Patent number: 10519219Abstract: The present invention provides antibodies, for use in the treatment, suppression prevention of Filovirus disease, particularly Ebola virus disease. Also provided immunogens for use in eliciting such antibodies.Type: GrantFiled: February 10, 2016Date of Patent: December 31, 2019Assignees: The Secretary of State for Health, MicroPharm Limited, The Chancellor, Masters and Scholars of the University of OxfordInventors: Miles Carroll, Stuart Dowall, Roger Hewson, Ian Cameron, John Landon, Antra Zeltina, David Stuart, Thomas Bowden
-
Patent number: 10059747Abstract: The present invention provides a viral vector or bacterial vector, said vector comprising a nucleic acid sequence encoding a Crimean-Congo Haemorrhagic Fever Virus (CCHFV) glycoprotein or antigenic fragment thereof; wherein said vector is capable of inducing an immune response in a subject. The present invention also provides compositions and uses of the vector in methods of medical treatment.Type: GrantFiled: November 29, 2013Date of Patent: August 28, 2018Assignee: THE SECRETARY OF STATE FOR HEALTHInventors: Karen Buttigieg, Mile Carroll, Roger Hewson, Stuart Dowall, Stephen Findlay-Wilson, Aleksandra Miloszewska
-
Patent number: 9982039Abstract: There is provided an antigenic composition comprising (a) a first mycobacterial antigenic polypeptide or a first mycobacterial polynucleotide; and (b) a second mycobacterial antigenic polypeptide or a second mycobacterial polynucleotide; wherein: (i) said first mycobacterial antigenic polypeptide comprises a polypeptide sequence having at least 70% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 1 or 7, or a fragment thereof having at least 7 consecutive amino acids thereof; (ii) said first mycobacterial polynucleotide comprises a polynucleotide sequence encoding said first mycobacterial antigenic polypeptide; (iii) said second mycobacterial antigenic polypeptide comprises a polypeptide sequence having at least 70% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 5, or a fragment thereof having at least 7 consecutive amino acids thereof; and (iv) said second mycobacterial polynucleotide comprises a polynucleotide sequence encoding said second mycobacterial polypeptidType: GrantFiled: April 14, 2016Date of Patent: May 29, 2018Assignee: The Secretary of State for HealthInventors: Miles Carroll, Yper Hall, Ann Williams
-
Publication number: 20180105580Abstract: The present invention provides antibodies, for use in the treatment, suppression prevention of Filovirus disease, particularly Ebola virus disease. Also provided immunogens for use in eliciting such antibodies.Type: ApplicationFiled: February 10, 2016Publication date: April 19, 2018Applicants: The Secretary of State for Health, MicroPharm Limited, The Chancellor, Masters and Scholars of the University of OxfordInventors: Miles Carroll, Stuart Dowall, Roger Hewson, Ian Cameron, John Landon, Antra Zeltina, David Stuart, Thomas Bowden
-
Publication number: 20170144969Abstract: The present disclosure relates to polyamine conjugates, its isomers, prodrugs and pharmaceutically acceptable salts thereof. The present disclosure also relates to process of preparation of polyamine conjugates, its stereoisomers, prodrugs, pharmaceutically acceptable salts thereof, and to pharmaceutical compositions containing them. The compounds of the present disclosure are useful in the treatment, prevention or suppression of diseases mediated by microbes.Type: ApplicationFiled: March 13, 2015Publication date: May 25, 2017Applicants: The Secretary of State for Health, Jawaharlal Nehru Centre for Advanced Scientific ResearchInventors: Miles Carroll, Jayanta Haldar, Mohini Mohan Konai
-
Publication number: 20160251415Abstract: There is provided an antigenic composition comprising (a) a first mycobacterial antigenic polypeptide or a first mycobacterial polynucleotide; and (b) a second mycobacterial antigenic polypeptide or a second mycobacterial polynucleotide; wherein: (i) said first mycobacterial antigenic polypeptide comprises a polypeptide sequence having at least 70% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 1 or 7, or a fragment thereof having at least 7 consecutive amino acids thereof; (ii) said first mycobacterial polynucleotide comprises a polynucleotide sequence encoding said first mycobacterial antigenic polypeptide; (iii) said second mycobacterial antigenic polypeptide comprises a polypeptide sequence having at least 70% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 5, or a fragment thereof having at least 7 consecutive amino acids thereof; and (iv) said second mycobacterial polynucleotide comprises a polynucleotide sequence encoding said second mycobacterial polypeptidType: ApplicationFiled: April 14, 2016Publication date: September 1, 2016Inventors: Miles Carroll, Yper Hall, Ann Williams
-
Patent number: 9339534Abstract: There is provided an antigenic composition comprising (a) a first mycobacterial antigenic polypeptide or a first mycobacterial polynucleotide; and (b) a second mycobacterial antigenic polypeptide or a second mycobacterial polynucleotide; wherein: (i) said first mycobacterial antigenic polypeptide comprises a polypeptide sequence having at least 70% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 1 or 7, or a fragment thereof having at least 7 consecutive amino acids thereof; (ii) said first mycobacterial polynucleotide comprises a polynucleotide sequence encoding said first mycobacterial antigenic polypeptide; (iii) said second mycobacterial antigenic polypeptide comprises a polypeptide sequence having at least 70% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 5, or a fragment thereof having at least 7 consecutive amino acids thereof; and (iv) said second mycobacterial polynucleotide comprises a polynucleotide sequence encoding said second mycobacterial polypeptidType: GrantFiled: May 23, 2011Date of Patent: May 17, 2016Assignee: The Secretary Of State For HealthInventors: Miles Carroll, Yper Hall, Ann Williams
-
Publication number: 20150361141Abstract: The present invention provides a viral vector or bacterial vector, said vector comprising a nucleic acid sequence encoding a Crimean-Congo Haemorrhagic Fever Virus (CCHFV) glycoprotein or antigenic fragment thereof; wherein said vector is capable of inducing an immune response in a subject. The present invention also provides compositions and uses of the vector in methods of medical treatment.Type: ApplicationFiled: November 29, 2013Publication date: December 17, 2015Inventors: Karen BUTTIGIEG, Mile CARROLL, Roger HEWSON, Stuart DOWALL, Stephen FINDLAY-WILSON, Aleksandra MILOSZEWSKA
-
Publication number: 20130217116Abstract: There is provided an MHC class II peptide epitope from 5T4 antigen. In particular, there is provided a peptide epitope of 5T4 which comprises one of the following: (i) the minimal epitope from the amino acid sequence shown as SEQ ID No. 2; (ii) the minimal epitope from the amino acid sequence shown as SEQ ID No. 3; (iii) a minimal epitope from the region 281-420 of 5T4. There is also provided a vaccine comprising such a peptide (or precursor thereof) and its use to treat and/or prevent a disease, in particular a cancerous disease.Type: ApplicationFiled: January 31, 2011Publication date: August 22, 2013Inventors: Miles Carroll, Richard Harrop, Susan Kingsman
-
Publication number: 20130142800Abstract: There is provided an antigenic composition comprising (a) a first mycobacterial antigenic polypeptide or a first mycobacterial polynucleotide; and (b) a second mycobacterial antigenic polypeptide or a second mycobacterial polynucleotide; wherein: (i) said first mycobacterial antigenic polypeptide comprises a polypeptide sequence having at least 70% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 1 or 7, or a fragment thereof having at least 7 consecutive amino acids thereof; (ii) said first mycobacterial polynucleotide comprises a polynucleotide sequence encoding said first mycobacterial antigenic polypeptide; (iii) said second mycobacterial antigenic polypeptide comprises a polypeptide sequence having at least 70% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 5, or a fragment thereof having at least 7 consecutive amino acids thereof; and (iv) said second mycobacterial polynucleotide comprises a polynucleotide sequence encoding said second mycobacterial polypeptidType: ApplicationFiled: May 23, 2011Publication date: June 6, 2013Applicant: HEALTH PROTECTION AGENCYInventors: Miles Carroll, Yper Hall, Ann Williams
-
Publication number: 20110165668Abstract: There is provided an MHC class I peptide epitope from 5T4 antigen. In particular, there is provided a peptide epitope of 5T4 which comprises one of the following: (i) the amino acid sequence shown as SEQ ID NO: 2; (ii) the minimal epitope from the amino acid sequence shown as SEQ ID NO: 3; (iii) the minimal epitope from the amino acid sequence shown as SEQ ID NO: 4; (iv) the minimal epitope from the amino acid sequence shown as SEQ ID NO: 5; (v) the minimal epitope from the amino acid sequence shown as SEQ ID NO: 6; (vi) the minimal epitope from the amino acid sequence shown as SEQ ID NO: 7. There is also provided a vaccine comprising such a peptide (or precursor thereof) and its use to treat and/or prevent a disease, in particular a cancerous disease.Type: ApplicationFiled: January 3, 2011Publication date: July 7, 2011Applicant: OXFORD BIOMEDICA (UK) LIMITEDInventors: Miles Carroll, Susan Kingsman, Irina Redchenko
-
Patent number: 7910109Abstract: There is provided an MHC class II peptide epitope from 5T4 antigen. In particular, there is provided a peptide epitope of 5T4 which comprises one of the following: (i) the minimal epitope from the amino acid sequence shown as SEQ ID No. 2; (ii) the minimal epitope from the amino acid sequence shown as SEQ ID No. 3; (iii) a minimal epitope from the region 281-420 of 5T4. There is also provided a vaccine comprising such a peptide (or precursor thereof) and its use to treat and/or prevent a disease, in particular a cancerous disease.Type: GrantFiled: February 13, 2003Date of Patent: March 22, 2011Assignee: Oxford Biomedica (UK) Ltd.Inventors: Miles Carroll, Susan Kingsman, Richard Harrop
-
Publication number: 20100310584Abstract: The present invention relates to a novel method for the delivery of agents to tumour cells. In particular it relates to a method for the specific delivery of agents to the interior of tumour cells. Uses of the method are also described.Type: ApplicationFiled: October 21, 2009Publication date: December 9, 2010Applicant: OXFORD BIOMEDICA (UK) LIMITEDInventors: Miles Carroll, Abigail Lamikanra, Alan Kingsman
-
Publication number: 20100086995Abstract: There is provided an MHC class I peptide epitope from 5T4 antigen. In particular, there is provided a peptide epitope of 5T4 which comprises one of the following: (i) the amino acid sequence shown as SEQ ID No.2; (ii) the minimal epitope from the amino acid sequence shown as SEQ ID No.3; (iii) the minimal epitope from the amino acid sequence shown as SEQ ID No.4. (iv) the minimal epitope from the amino acid sequence shown as SEQ ID No. 5. (v) the minimal epitope from the amino acid sequence shown as SEQ ID No.6. (vi) the minimal epitope from the amino acid sequence shown as SEQ ID No.7. There is also provided a vaccine comprising such a peptide (or precursor thereof) and its use to treat and/or prevent a disease, in particular a cancerous disease.Type: ApplicationFiled: July 10, 2009Publication date: April 8, 2010Applicant: OXFORD BIOMEDICA (UK) LIMITEDInventors: Miles Carroll, Susan Kingsman, Irina Redchenko
-
Patent number: 7575916Abstract: There is provided an MHC class I peptide epitope from 5T4 antigen. In particular, there is provided a peptide epitope of 5T4 which comprises one of the following: (i) the amino acid sequence shown as SEQ ID No. 2; (ii) the minimal epitope from the amino acid sequence shown as SEQ ID No. 3; (iii) the minimal epitope from the amino acid sequence shown as SEQ ID No. 4. (iv) the minimal epitope from the amino acid sequence shown as SEQ ID No. 5. (v) the minimal epitope from the amino acid sequence shown as SEQ ID No. 6. (vi) the minimal epitope from the amino acid sequence shown as SEQ ID No. 7. There is also provided a vaccine comprising such a peptide (or precursor thereof) and its use to treat and/or prevent a disease, in particular a cancerous disease. There is also provided a nucleic acid molecule encoding a MHC class I peptide epitope from the human 5T4 tumor-associated antigen and vector comprising the nucleic acid molecule.Type: GrantFiled: February 13, 2003Date of Patent: August 18, 2009Assignee: Oxford Biomedica (UK) LimitedInventors: Miles Carroll, Susan Kingsman, Irina Redchenko
-
Publication number: 20090155290Abstract: The present invention relates to a novel method for the delivery of agents to tumour cells. In particular it relates to a method for the specific delivery of agents to the interior of tumour cells. Uses of the method are also described.Type: ApplicationFiled: December 10, 2008Publication date: June 18, 2009Applicant: OXFORD BIOMEDICA (UK) LIMITEDInventors: Miles Carroll, Abigail Lamikanra, Alan Kingsman
-
Patent number: 7541044Abstract: The invention provides the use of an enzyme and a prodrug in the manufacture of a medicament for use in inducing an anti-tumor immune response in a human patient.Type: GrantFiled: September 29, 2006Date of Patent: June 2, 2009Assignee: Oxford Biomedica (UK) LimitedInventors: Richard Harrop, Miles Carroll, Susan Kingsman
-
Publication number: 20080279854Abstract: Canine and feline 5T4 polypeptide sequences and nucleotide sequences encoding them are provided. A vector system comprising a nucleic acid encoding 5T4 and a 5T4-specific agent are also provided.Type: ApplicationFiled: July 7, 2008Publication date: November 13, 2008Applicant: OXFORD BIOMEDICA (UK) LIMITEDInventors: Kevin Myers, Noel Drury, Miles Carroll
-
Publication number: 20080274542Abstract: Canine and feline 5T4 polypeptide sequences and nucleotide sequences encoding them are provided. A vector system comprising a nucleic acid encoding 5T4 and a 5T4-specific agent are also provided.Type: ApplicationFiled: July 8, 2008Publication date: November 6, 2008Applicant: OXFORD BIOMEDICA (UK) LIMITEDInventors: Kevin Myers, Noel Drury, Miles Carroll